Anxiolytic management in eating disorder patients receiving cognitive behavioral therapy: A quality improvement brief report

Sheldon R Garrison,Brad E.R. Smith,Katelyn A. Greenberg,Sreya Vadapalli
DOI: https://doi.org/10.1101/2024.11.25.24317936
2024-11-27
Abstract:Eating disorders (EDs) are serious lifelong and debilitating health conditions characterized by complex adverse eating behaviors resulting in weight loss and decreased quality of life. One evidence-based treatment is a form of cognitive-behavioral therapy (CBT) called exposure therapy where patients progress through a hierachy of exposures. This treatment approach results in concern related to CBT efficacy for patients concurrently treated with anxiolytic medications. These medications, which are being incorporated into treatment protocols, may impact the anxiety-provoking components of the exposure response, potentially limiting its efficacy. Therefore, patients were assessed in multiple ways to ensure that providers could prescribe anxiolytics without risk to diminishing the well-established response to CBT. To ensure that patients treated with anxiolytics progressed at a similar rate to those who did not receive them, a quality improvement study was conducted to compare all patients in residential, partial hospitalization and intensive outpatient eating disorder treatment programs.
Psychiatry and Clinical Psychology
What problem does this paper attempt to address?